<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037699</url>
  </required_header>
  <id_info>
    <org_study_id>0502-C-M05-EB</org_study_id>
    <nct_id>NCT01037699</nct_id>
  </id_info>
  <brief_title>Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation
      controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and
      patients aged between 36 and 39 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0
      mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation,
      patients started ovarian stimulation as follows:

      Patients &lt; 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of
      rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist
      Cetrorelix is added until the day of rCG administration.

      Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and
      75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH
      antagonist Cetrorelix is added until the day of rCG administration.

      A maximum of 3 embryos were transferred on day 3 of embryo development.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4 weeks after embryo transfer</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>FSH YOUNGER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH OLDER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH LH YOUNGER (Recombinant Luteotrophin alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH LH OLDER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH: Follicle Stimulating Hormone</intervention_name>
    <arm_group_label>FSH YOUNGER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH: Follicle Stimulating Hormone</intervention_name>
    <arm_group_label>FSH OLDER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)</intervention_name>
    <arm_group_label>FSH LH YOUNGER (Recombinant Luteotrophin alfa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)</intervention_name>
    <arm_group_label>FSH LH OLDER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st-2nd IVF cycle.

          -  Age until 39 years old

          -  BMI: 18-29.9.

          -  Basal FSH &lt; 12 IU/L

        Exclusion Criteria:

          -  LH:FSH &gt; 2 (PCO)

          -  Low response background (&lt; 5 oocytes)

          -  Endometrioma

          -  Recurrent pregnancy loss

          -  Any preimplantational genetic diagnosis indication

          -  Any systemic, metabolic or endocrinological disorder.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernesto Bosch, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46117</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>December 22, 2009</last_update_submitted>
  <last_update_submitted_qc>December 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ernesto Bosch</name_title>
    <organization>IVI Valencia</organization>
  </responsible_party>
  <keyword>Ovarian stimulation</keyword>
  <keyword>In Vitro Fertilization</keyword>
  <keyword>Luteinizing Hormone</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>Implantation rate in infertile patients undergoing In vitro fertilization and embryo transfer.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

